Pages that link to "Q37408608"

The following pages link to Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer (Q37408608):

Displaying 40 items.

• Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. (Q30409623) (← links)
• Using high-density DNA methylation arrays to profile copy number alterations. (Q33742976) (← links)
• Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer (Q33894922) (← links)
• Mouse models of prostate cancer: picking the best model for the question. (Q33940867) (← links)
• Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. (Q34016615) (← links)
• Genomics screens for metastasis genes (Q34298860) (← links)
• Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors (Q34452275) (← links)
• A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors (Q35009891) (← links)
• Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men. (Q35281575) (← links)
• Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers (Q35345680) (← links)
• Detection of somatic copy number alterations in cancer using targeted exome capture sequencing (Q35571880) (← links)
• Overexpression of IL-7 enhances cisplatin resistance in glioma (Q36000273) (← links)
• Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study (Q36296457) (← links)
• Genomic and epigenomic alterations in prostate cancer. (Q36374578) (← links)
• Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer (Q36468744) (← links)
• High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer (Q36468773) (← links)
• Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures (Q36580194) (← links)
• A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer (Q36784513) (← links)
• Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. (Q36998629) (← links)
• Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification (Q37067529) (← links)
• Translational and clinical implications of the genetic landscape of prostate cancer (Q37270512) (← links)
• What is the pathophysiology of a hormone-resistant prostate tumour? (Q37937865) (← links)
• Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. (Q38207592) (← links)
• PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality (Q39181062) (← links)
• The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression (Q39628604) (← links)
• Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer (Q41345175) (← links)
• The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression (Q41842962) (← links)
• A transgenic mouse model for early prostate metastasis to lymph nodes (Q41864582) (← links)
• The genomic landscape of prostate cancer (Q42174920) (← links)
• LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. (Q42315779) (← links)
• Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer (Q42322498) (← links)
• PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer (Q45251986) (← links)
• PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade (Q45359397) (← links)
• Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. (Q52566012) (← links)
• Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. (Q54494653) (← links)
• PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications (Q57790325) (← links)
• Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery (Q89174568) (← links)
• Transcriptional regulators and regulatory pathways involved in prostate gland adaptation to a hypoandrogen environment (Q90229201) (← links)
• Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation (Q90707592) (← links)
• Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy (Q92410897) (← links)